Phaseline

Companies › Jiangsu Hansoh Pharmaceutical

Jiangsu Hansoh Pharmaceutical: clinical trials, targets and expected readouts

12 active drug programs in 32 registered trials: 17 Phase 1, 8 Phase 3, 6 Phase 2, 1 Phase 4; Oncology, Other, Hematology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tenofovir Amibufenamide (TMF)
Nucleotide reverse transcriptase inhibitor (NRTi) - prodrug of tenofovir
POLR2APhase 4Hepatitis B, ChronicSep 2029
HS-10504
EGFR C797S mutation-targeting tyrosine kinase inhibitor
EGFRPhase 3Advanced or Metastatic NSCLC; Locally Advanced or Metastatic NSCLCDec 2026
Aumolertinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Non-small Cell Lung Cancer; Non Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Lung Cancer …Jan 2027
HS-10365
RET inhibitor
RETPhase 2Nonsmall Cell Lung CancerAug 2027
HS-20118–Phase 1Psoriasis; Healthy ParticipantsDec 2026
HS-10542–Phase 1Healthy; Paroxysmal Nocturnal HemoglobinuriaMay 2027
HS-10516
HIF-2α inhibitor
HIF2APhase 1Advanced Clear Cell Renal Cell Carcinoma; Von Hippel Lindau-Deficient Clear Cell Renal Cell CarcinomaJul 2027
HS-10386–Phase 1Advanced Solid TumorOct 2027
HS-10566
Intravesical gemcitabine delivery system
RRM1, RRM2, DCKPhase 1High-risk Non-muscle-invasive Bladder CancerApr 2028
HS-10506–Phase 1Hepatic Impairment (Moderate or Mild) & Normal Hepatic FunctionJun 2028
HS-10502
PARP1-specific selective inhibitor
PARP1Phase 1Ovarian Cancer; Recurrent Ovarian Cancer–
HS-20094
GLP-1 receptor agonist
–Phase 1Overweight or Obesity–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04923906AumolertinibPhase 3Non-small Cell Lung CancerOncologyJun 2024
NCT06926413AumolertinibPhase 1Non Small Cell Lung CancerOncologyOct 2025
NCT06924398AumolertinibPhase 2Lung Cancer (NSCLC)OncologyDec 2025
NCT07040046HS-10542Phase 1HealthyOtherDec 2025
NCT06300424AumolertinibPhase 2Non Small Cell Lung CancerOncologyJan 2026
NCT07057674HS-20094Phase 1Overweight or ObesityMetabolic and endocrineFeb 2026
NCT07033234HS-20118Phase 1PsoriasisImmunologyMar 2026
NCT05740956HS-10502Phase 1Ovarian CancerOncologyApr 2026
NCT06769425HS-10502Phase 1Recurrent Ovarian CancerOncologyMay 2026
NCT06846710HS-20118Phase 1PsoriasisImmunologyJul 2026
NCT07896915HS-20118Phase 1Healthy ParticipantsOtherDec 2026
NCT04841811AumolertinibPhase 3Lung CancerOncologyDec 2026
NCT06461156HS-10504Phase 1Locally Advanced or Metastatic NSCLCOncologyDec 2026
NCT04951635AumolertinibPhase 3Non-small Cell Lung CancerOncologyJan 2027
NCT06947811AumolertinibPhase 1EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 InhibitorOtherMar 2027
NCT06951464AumolertinibPhase 2Non-Small Cell Lung CancerOncologyMay 2027
NCT07470762HS-10542Phase 1Paroxysmal Nocturnal HemoglobinuriaHematologyMay 2027
NCT06043973AumolertinibPhase 3Advanced Non-small Cell Lung CancerOncologyJun 2027
NCT07097935HS-10516Phase 1Advanced Clear Cell Renal Cell CarcinomaOncologyJul 2027
NCT06147570HS-10365Phase 2Nonsmall Cell Lung CancerOncologyAug 2027
NCT05911464HS-10386Phase 1Advanced Solid TumorOncologyOct 2027
NCT05800223AumolertinibPhase 3Non-small Cell Lung Cancer MetastaticOncologyDec 2027
NCT07130916AumolertinibPhase 1Non-Small Cell Lung CancerOncologyDec 2027
NCT04685070AumolertinibPhase 2Non-small Cell Lung Cancer Stage IIIOncologyDec 2027
NCT07468851HS-10566Phase 1High-risk Non-muscle-invasive Bladder CancerOncologyApr 2028
NCT07844967HS-10506Phase 1Hepatic Impairment (Moderate or Mild) & Normal Hepatic FunctionOncologyJun 2028
NCT06553339HS-10516Phase 1Von Hippel Lindau-Deficient Clear Cell Renal Cell CarcinomaOncologyJul 2028
NCT07754123HS-10504Phase 3Advanced or Metastatic NSCLCOncologyAug 2028
NCT05768490AumolertinibPhase 3Brain MetastasesOncologyDec 2028
NCT07624487AumolertinibPhase 2Lung Adenocarcinoma MetastaticOncologyDec 2028
NCT04687241AumolertinibPhase 3Non-small Cell Lung CancerOncologyJan 2029
NCT06743438Tenofovir Amibufenamide (TMF)Phase 4Hepatitis B, ChronicInfectious diseaseSep 2029

Targets

EGFR (2) PARP1 (1) HIF2A (1) POLR2A (1) RET (1) RRM1 (1) RRM2 (1) DCK (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Allist Pharmaceuticals Johnson & Johnson (Janssen) Dizal Pharmaceuticals Betta Pharmaceuticals Henan Genuine Biotech Merck & Co. (MSD) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Companies built like this

Sunshine Lake Pharma Abbisko Therapeutics Haisco Pharmaceutical Group Jiangsu Simcere Pharmaceutical Sichuan Kelun-Biotech Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.